Search - tctmd.com

Displaying 1 - 7 of 7

Sort: Relevancy | Date

Presentation ARCH 2022

Monitoring Post ACS Patients: Novel Device to Reduce “Time to Door” for ACS Events

Presenter: Jasvindar Singh

April 23, 2022

Presentation CCVVC 2016

Novel Anti-thrombotics in Patients with Peripheral Artery Disease

Presenter: Marc P. Bonaca

June 15, 2016

Presentation

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Presenter: Vivek Y. Reddy

December 13, 2015

Presentation TCT 2014

Comparison of Novel Zotarolimus-Eluting Cobalt-Chromium Stents and Everolimus-Eluting Platinum-Chromium Stents in Patients of the Randomized DUTCH PEERS Trial Presenting with___

Presenter: Marije L?wik

September 16, 2014

Presentation TCT 2012

Novel Anticoagulants in Patients with Acute Coronary Syndromes

Presenter: C. Michael Gibson

October 25, 2012

Presentation TCT 2012

TCT-112: Two-Way Real-time Interaction by Means of a Novel Telecommunications Software Improves Management of Patients with ST-Segment Elevation Myocardial Infarction

Presenter: Gabriel Sardi

October 22, 2012

Presentation

Everolimus-Eluting Versus Novolimus-Eluting Bioresorbable Scaffolds for CAD

Presenter: Jens Wiebe

February 16, 0017

Advertisement

Monitoring Post ACS Patients: Novel Device to Reduce “Time to Door” for ACS Events

Novel Anti-thrombotics in Patients with Peripheral Artery Disease

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Comparison of Novel Zotarolimus-Eluting Cobalt-Chromium Stents and Everolimus-Eluting Platinum-Chromium Stents in Patients of the Randomized DUTCH PEERS Trial Presenting with___

Novel Anticoagulants in Patients with Acute Coronary Syndromes

TCT-112: Two-Way Real-time Interaction by Means of a Novel Telecommunications Software Improves Management of Patients with ST-Segment Elevation Myocardial Infarction

Everolimus-Eluting Versus Novolimus-Eluting Bioresorbable Scaffolds for CAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content